B+
Bull case
30%
Probability
Target price
$620.00
Analysis reference price unavailable
Analysis 2026-08-06 · RankAlpha Sentiment Codex
VRTX
VertexANasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexPost-earnings T+3Most likely
B
Base case
50%
Probability
Target price
$563.83
Analysis reference price unavailable
Analysis 2026-08-06 · RankAlpha Sentiment Codex
B-
Bear case
20%
Probability
Target price
$430.00
Analysis reference price unavailable
Analysis 2026-08-06 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-08-06
Recent news sentiment (30D)
-
Unavailable
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
+71.4
Score
AI commentary
The company-source evidence is concrete: the SEC-filed Q2 exhibit reports $3.33 billion of revenue, raised FY2026 guidance, the povetacicept PDUFA date, and the pending Crinetics acquisition. The packet's IBD headline reports that shares fell despite the guidance raise, indicating a mixed immediate reaction, but it provides no quantified post-print move or verified attribution. Pre-release Zacks estimates are available, while post-print analyst revisions and target changes remain unavailable. Social coverage is absent, so this remains a positive but monitoring-oriented view.
RankAlpha Sentiment Codex - 2026-08-06
Open post-earnings memoEvidence flagged
later post-earnings follow-up lacks concrete company-source and analyst/market reaction evidence
Impact
tentative
Confidence
-
AI events
2026-08-03eventQ2 revenue growth and FY2026 guidance increaseMedium impact
Vertex reported Q2 revenue of $3.33 billion, up 12% year over year, versus a pre-release Zacks forecast of $3.23 billion, and raised FY2026 revenue guidance to $13.1-$13.2 billion from $12.95-$13.1 billion. The company cited CF demand, ALYFTREK uptake, CASGEVY, and JOURNAVX as drivers. [#SEC-8K-2026-08-03] [#PR-EARNINGS-2026-07-29]
2026-11-30eventPovetacicept regulatory decisionHigh impact
The Q2 update identifies a November 30, 2026 PDUFA date for povetacicept, creating a binary regulatory catalyst in IgA nephropathy. The approval outcome is not yet established. [#SEC-8K-2026-08-03]
2026-12-31catalystCommercial diversification and Crinetics transactionHigh impact
Continued global ALYFTREK and TRIKAFTA growth, at least $500 million of expected non-CF revenue, and the pending Crinetics acquisition could broaden Vertex beyond cystic fibrosis. Closing is anticipated in Q3 2026 subject to customary conditions; current 2026 guidance excludes the acquisition's impact and is expected to be updated after closing. [#SEC-8K-2026-08-03]
Recommendation
N/A
No formal recommendation provided.
As of 2026-08-06 • Updated nightlySource: Internal modelMethodology